Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
The Journal of Infectious Diseases
|
August 21, 2004
Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy
Cunlin Wang, David Vlahov, Noya Galai, et al.
AIDS (London, England)
|
May 21, 2005
The effect of HIV infection on overdose mortality
Cunlin Wang, David Vlahov, Noya Galai, et al.
Substance Use & Misuse
|
March 28, 2008
Mortality risk among recent-onset injection drug users in five U.S. cities
David Vlahov, Cunlin Wang, Danielle Ompad, et al.
Clinical and Translational Science
|
September 4, 2024
Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers
Hengbang Wang, Yun Yang, Zi Chen, et al.
The Journal of Bone and Joint Surgery. American Volume
|
November 10, 2012
Risk of revision for fixed versus mobile-bearing primary total knee replacements
Robert S Namba, Maria C S Inacio, Elizabeth W Paxton, et al.
JAMA Internal Medicine
|
February 20, 2013
Sex and risk of hip implant failure: assessing total hip arthroplasty outcomes in the United States
Maria C S Inacio, Christopher F Ake, Elizabeth W Paxton, et al.
Pharmacoepidemiology and Drug Safety
|
November 5, 2015
Trends in rates of acetaminophen-related adverse events in the United States
Jacqueline M Major, Esther H Zhou, Hui-Lee Wong, et al.
JAMA
|
November 18, 2015
Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products
Cunlin Wang, David J Graham, Robert C Kane, et al.
JAMA Internal Medicine
|
October 25, 2016
Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare
Cunlin Wang, Robert Kane, Mark Levenson, et al.
JAMA Oncology
|
November 21, 2024
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial
Elias Jabbour, Vivian G Oehler, Paul B Koller, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
The Journal of Infectious Diseases
|
August 21, 2004
Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy
Cunlin Wang, David Vlahov, Noya Galai, et al.
AIDS (London, England)
|
May 21, 2005
The effect of HIV infection on overdose mortality
Cunlin Wang, David Vlahov, Noya Galai, et al.
Substance Use & Misuse
|
March 28, 2008
Mortality risk among recent-onset injection drug users in five U.S. cities
David Vlahov, Cunlin Wang, Danielle Ompad, et al.
Clinical and Translational Science
|
September 4, 2024
Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers
Hengbang Wang, Yun Yang, Zi Chen, et al.
The Journal of Bone and Joint Surgery. American Volume
|
November 10, 2012
Risk of revision for fixed versus mobile-bearing primary total knee replacements
Robert S Namba, Maria C S Inacio, Elizabeth W Paxton, et al.
JAMA Internal Medicine
|
February 20, 2013
Sex and risk of hip implant failure: assessing total hip arthroplasty outcomes in the United States
Maria C S Inacio, Christopher F Ake, Elizabeth W Paxton, et al.
Pharmacoepidemiology and Drug Safety
|
November 5, 2015
Trends in rates of acetaminophen-related adverse events in the United States
Jacqueline M Major, Esther H Zhou, Hui-Lee Wong, et al.
JAMA
|
November 18, 2015
Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products
Cunlin Wang, David J Graham, Robert C Kane, et al.
JAMA Internal Medicine
|
October 25, 2016
Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare
Cunlin Wang, Robert Kane, Mark Levenson, et al.
JAMA Oncology
|
November 21, 2024
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial
Elias Jabbour, Vivian G Oehler, Paul B Koller, et al.
Page
of 2